Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents (DIVA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ambika Ashraf, M.D., University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01041365
First received: December 28, 2009
Last updated: January 13, 2014
Last verified: January 2014
  Purpose

The overall objectives of this study are to examine the relationships between circulating vitamin D, insulin sensitivity, and multiple indices of vascular function and to examine whether vitamin D deficiency in AA is responsible for ethnic differences in insulin sensitivity and hypertension in AA and EA, as well as mechanisms underlying the association between insulin resistance and blood pressure. We hypothesize that 1) serum 25(OH)D is associated with insulin sensitivity and vascular functioning, independent of adiposity, 2) lower insulin sensitivity and vascular functioning in AA relative to EA is due to lower circulating 25(OH)D in AA, and 3) the relationship between insulin resistance and vascular dysfunction is mediated by 25(OH)D.

Acronyms: African American (AA), European American (EA), Serum 25-hydroxy vitamin D (25()H)D, Body mass index (BMI), Alabama (AL).


Condition
Insulin Sensitivity
Flow-mediated Dilation
Arterial Stiffness

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Serum 25-hydroxyvitamin D, Vascular Functioning, and Insulin Sensitivity in Adolescent Girls [The DIVA Study (Vitamin D, Insulin, and Vascular Associations)] (Pediatric Physician Training in Translational Research)

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • Insulin Sensitivity [ Time Frame: Cross sectional study: at the first study visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Vascular Function [ Time Frame: Cross sectional study: at the second study visit, within 2 weeks of first study visit ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum


Enrollment: 62
Study Start Date: December 2009
Study Completion Date: December 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Healthy adolescents
Healthy adolescent African American and Caucasian females, ages 14-18

  Eligibility

Ages Eligible for Study:   14 Years to 18 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy adolescent African American and European American teenagers, ages 14-18, will be recruited form the Birmingham, AL community

Criteria

Inclusion Criteria:

  • African American or Caucasian ethnicity
  • Ages 14-18 yrs
  • Healthy

Exclusion Criteria:

  • BMI-for age and -sex higher than 95th centile on the Centers for Disease Control and Prevention Growth Charts
  • Use of medication(s) known to influence body composition, vascular function, or glucose metabolism
  • Pregnancy
  • Diabetes or any chronic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01041365

Locations
United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35243
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: Ambika Ashraf, MD University of Alabama at Birmingham
  More Information

No publications provided by University of Alabama at Birmingham

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ambika Ashraf, M.D., Associate Professor, Pediatrics, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT01041365     History of Changes
Other Study ID Numbers: F090824002
Study First Received: December 28, 2009
Last Updated: January 13, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:
insulin sensitivity
vascular function
flow-mediated dilation
arterial stiffness
ethnicity
adolescents
females
glucose tolerance
diabetes
hypertension
cardiovascular

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Hyperinsulinism
Metabolic Diseases
Insulin
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 20, 2014